Lonza has made an investment in Cilian. The deal gives Lonza right of first refusal for the commercial production of products and access to Cilian's ciliates system for the production of therapeutic proteins and nutritional ingredients. Lonza will transfer a number of patents and patent applications in tis field to Cilian in return for newly issued shares in Cilian.
Lonza
Thursday 22 October 2009
Lonza acquires stake in German biotech, Cilian
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment